Stocks in the news 7

BPAX
BioSante Pharmaceuticals Receives Two New Patents for Manufacture of Proteins, Including Antibodies..http://bit.ly/bbBDZf
AEZS
terna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for Perifosine for the Treatment of Multiple Myeloma from the Committee for Orphan Medicinal Products of the European Medicines Agency..http://bit.ly/co08zF
KERX
Æterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for Perifosine for the Treatment of Multiple Myeloma from the Committee for Orphan Medicinal Products of the European Medicines Agency
Keryx Biopharmaceuticals, Inc.  (Nasdaq: KERX), Æterna Zentaris’ partner and licensee for perifosine in the North American market, already announced in  September 2009  that it has received Orphan Drug Designation for perifosine for the treatment of multiple myeloma from the  U.S. Food and Drug Administration  ( FDA ).
GHLV
Global Health Selects Sites for the European Clinical Trials of X-Excite, Its Male Sexual Enhancement Drug.. http://bit.ly/al5Eck
HTDS
Hard to Treat Diseases’ (HTDS) ‘Nutriprotein’ Reached the Final Approval Stage in India
http://bit.ly/a83Kyg

Follow us on twitter. http://bit.ly/dsbNrf

Tagged as: Approval Stage, Biopharmaceuticals, European Medicines, Food And Drug Administration, Food And Drug Administration Fda, Global Health, Hard To Treat Diseases, Htds, Kerx, Keryx Biopharmaceuticals Inc, Male Sexual Enhancement, Medicines Agency, Multiple Myeloma, Nasdaq, Orphan Drug Designation, Orphan Medicinal Products, Perifosine, Product Designation, Terna, Zentaris